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ABSTRACT 
Background: While high-risk mutations in identified major susceptibility genes (DNA 
mismatch repair genes and MUTYH) account for some familial aggregation of colorectal 
cancer, their population prevalence and the causes of the remaining familial aggregation are 
not known. 
Methods: We studied the families of 5,744 colorectal cancer cases (probands) recruited from 
population cancer registries in the USA, Canada and Australia and screened probands for 
mutations in mismatch repair genes and MUTYH. We conducted modified segregation 
analyses using the cancer history of first-degree relatives, conditional on the proband’s age at 
diagnosis. We estimated the prevalence of mutations in the identified genes, the prevalence of 
and hazard ratio for unidentified major gene mutations, and the variance of the residual 
polygenic component. 
Results:  We estimated that 1 in 279 of the population carry mutations in mismatch repair 
genes (MLH1= 1 in 1946, MSH2= 1 in 2841, MSH6= 1 in 758, PMS2= 1 in 714), 1 in 45 
carry mutations in MUTYH, and 1 in 504 carry mutations associated with an average 31-fold 
increased risk of colorectal cancer in unidentified major genes. The estimated polygenic 
variance was reduced by 30-50% after allowing for unidentified major genes and decreased 
from 3.3 for age <40 years to 0.5 for age ≥70 years (equivalent to sibling relative risks of 5.1 
to 1.3, respectively).  
Conclusion: Unidentified major genes might explain one-third to one-half of the missing 
heritability of colorectal cancer.  
Impact: Our findings could aid gene discovery and development of better colorectal cancer 
risk prediction models. 
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INTRODUCTION  
One of the most important risk factors for colorectal cancer is having a family history of the 
disease. First-degree relatives of persons diagnosed with colorectal cancer are, on average, at 
an approximately two-fold increased risk of colorectal cancer compared with those without a 
family history (familial relative risk) (1). An estimated 3% to 5% of colorectal cancers are 
caused by high-risk mutations in the identified major colorectal cancer susceptibility 
genes(2): DNA mismatch repair (MMR) genes(3) and constitutional 3’ end deletions of 
EPCAM(4, 5) implicated in Lynch syndrome; the adenomatous polyposis coli (APC) gene 
implicated in familial adenomatous polyposis(6-8); and the MUTYH gene implicated in 
colorectal polyps and subsequently cancer (MUTYH-associated polyposis)(9). Current 
estimates of MMR gene mutation carriers in the general population, inferred from the 
prevalence of mutations in cases and the risk of colorectal cancer for carriers, range widely 
from approximately 1 in 300 to 1 in 3,000 depending on differing assumptions and genes (10-
16). With the availability of cost-effective sequencing technologies, improved precision in 
estimates of mutation prevalence would be useful for devising cost-effective genetic testing 
protocols. 
Less than half of the excess risk of colorectal cancer associated with family history 
(familial aggregation) is explained by mutations in the above identified genes, and only two 
studies have attempted to explain the remainder of the familial aggregation (17, 18). Aaltonen 
et al could not confidently distinguish between different modes of inheritance for the 
hypothetical unidentified major genes (17). Jenkins et al estimated that 1 in 588 of the 
population carry major gene mutations associated with a recessively inherited risk, and these 
mutations would explain 15% of all colorectal cancers diagnosed before age 45 years (18). 
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Both these studies relied on relatively small numbers of families and did not consider the 
existence of both polygenic and major genes.  
While much research has been conducted on the search for other major colorectal 
cancer susceptibility genes in addition to those described above, only a few have been 
confirmed (19). Genome-wide association studies have identified at least 45 independent 
genetic susceptibility markers (single-nucleotide polymorphisms, SNPs) that are reliably 
associated with small increments in the risk of developing colorectal cancer (20). 
The aim of this paper was to use population-based family data to estimate: the 
prevalence of mutations in the identified major colorectal cancer susceptibility genes (MMR 
genes and MUTYH); the prevalence, average penetrance, and likely mode of inheritance for 
the unidentified major gene mutations; and the variance of the residual polygenic component 
before and after allowing for different major gene scenarios. 
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MATERIALS AND METHODS 
Sample 
The sample consists of nuclear families from the Colon Cancer Family Registry 
which has been described in detail previously(21,22). The present study used data for the 
first-degree relatives of the incident colorectal cancer cases (probands) who had been 
recruited irrespective of family history from state or regional population cancer registries in 
the USA (Washington, California, Arizona, Minnesota, Colorado, New Hampshire, North 
Carolina), Australia (Victoria) and Canada (Ontario) between 1997 and 2012. Families were 
excluded if the proband was known to have an APC mutation. Informed consent was obtained 
from all study participants, and the study protocol was approved by the institutional research 
ethics review board at each recruiting site of the Colon Cancer Family Registry.  
Data Collection 
Information on demographics, personal characteristics, personal and family history of 
cancer, cancer-screening history, history of polyps, polypectomy, and other surgeries was 
obtained by questionnaires from all probands at baseline recruitment, which was about 1-2 
years after diagnosis of their colorectal cancer, and from all participating relatives. The 
questionnaires are available from the Colon Cancer Family Registry website(23). We sought 
confirmation of all reported cancer diagnoses and ages at diagnosis for relatives using 
pathology reports, medical records, cancer registry reports, and death certificates, where 
possible. We attempted to obtain blood or buccal samples from all participants and tumor 
tissue from all affected participants. 
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Mismatch Repair (MMR) gene mutation screening  
All probands had their colorectal cancers tested for MMR deficiency, defined by 
either tumor microsatellite instability (MSI) and/or lack of MMR protein expression by 
immunohistochemistry (IHC). Probands with a MMR-deficient tumor were screened for 
germline mutations in MMR genes. MLH1, MSH2 and MSH6 mutations were identified using 
Sanger sequencing or denaturing high performance liquid chromatography (dHPLC), 
followed by confirmatory DNA sequencing. Large duplication and deletion mutations 
including those involving EPCAM, which lead to MSH2 methylation, were detected by 
Multiplex Ligation Dependent Probe Amplification (MLPA) according to the manufacturer’s 
instructions (MRC Holland, Amsterdam, The Netherlands) (21,24,25). PMS2 mutations were 
identified using a modified protocol from Senter et al(26) where exons 1-5, 9 and 11-15 were 
amplified in three long range PCRs followed by nested exon specific PCR/sequencing. The 
remaining exons (6, 7, 8 and 10) were amplified and sequenced directly from genomic DNA. 
Large-scale deletions in PMS2 were detected using the P008-A1 MLPA kit according to 
manufacturers specifications (MRC Holland, Amsterdam, The Netherlands). Germline 
variants were classified for pathogenicity based on 5 class system for quantitative assessment 
of variant pathogenicity(27) and the application of a multifactorial likelihood model 
developed for MMR gene variants(28) as applied to variants catalogued within the InSiGHT 
database (29) where classes 4 and 5 were considered pathogenic (30). For variants not yet 
classified by InSiGHT, we considered a variant as pathogenic if it resulted in a stop codon, 
frameshift, large deletion, or if it removed a canonical splice site. The relatives of probands 
with a pathogenic MMR germline mutation, who provided a blood sample, underwent testing 
for the specific mutation identified in the proband.  
MUTYH mutation testing  
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Population-based probands were tested for 12 previously identified MUTYH variants: 
c.536A>G p.(Tyr179Cys), c.1187G>A p.(Gly396Asp), c.312C>A p.(Tyr104Ter), c.821G>A 
p.(Arg274Gln), c.1438G>T p.(Glu480Ter), c.1171C>T p.(Gln391Ter), c.1147delC 
p.(Ala385ProfsTer23), c.933+3A>C p.(Gly264TrpfsX7), c.1437_1439delGGA 
p.(Glu480del), c.721C>T, p.(Arg241Trp), c.1227_1228dup p.(Glu410GlyfsX43), and 
c.1187-2A>G p.(Leu397CysfsX89) using the MassArray MALDI-TOF Mass Spectrometry 
(MS) system (Sequenom, San Diego, CA) (31). To confirm the MUTYH mutation and 
identify additional mutations, screening of the entire MUTYH coding region, promoter, and 
splice site regions was performed on all samples exhibiting MS mobility shifts using 
denaturing high-performance liquid chromatography (Transgenomic Wave 3500HT System; 
Transgenomic, Omaha, NE). All MS-detected variants and WAVE mobility shifts were 
submitted for sequencing for mutation confirmation (ABI PRISM 3130XL Genetic 
Analyser). That is, if a heterozygous MUTYH mutation was identified, then the MUTYH gene 
was screened for any additional mutations not captured by the Sequenom genotyping screen 
to ensure all potential compound heterozygous carriers were identified. The relatives of 
probands with a pathogenic MUTYH germline mutation, who provided a blood sample, 
underwent testing for the specific variant identified in the proband. For the present study, 
MUTYH gene mutation status was recorded as monoallelic or biallelic mutation-positive or 
negative, with no distinction between different variants. 
Statistical Methods 
We used modified segregation analysis to fit a range of genetic models to the 
observed colorectal cancer family histories for the proband and their first-degree relatives. 
Individuals were assumed to be at risk of colorectal cancer from birth until the earliest of the 
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following: diagnosis of colorectal cancer or any other cancer (except skin cancer); first 
polypectomy; death; and the earlier of last known age at baseline interview or age 80 years.  
The colorectal cancer incidence λi(t,k) for individual i at age t in sex group k (k = 1 for 
males or 2 for females) was assumed to depend on genotype according to a parametric 
survival analysis model λi(t,k)=λ0(t,k) exp(Gi+Pi(t)), where λ0(t,k) is the sex-specific baseline 
incidence at age t . Gi is the natural logarithm of the relative risk associated with the major 
genotype and Pi(t) is the polygenic component for age t.  
The major genotype was defined by six components representing each of the genes 
MLH1, MSH2, MSH6, PMS2, MUTYH and one representing the hypothetical unidentified 
major genes. We fitted models in which the unidentified major genes were autosomal with a 
normal and a mutant allele unlinked to mutations in the MMR genes or MUTYH. We also 
fitted models in which the average relative risk for the unidentified major genes was assumed 
to be age dependent. We used the published age-, sex- and country-specific incidences for 
MLH1 and MSH2 mutation carriers (32), and published age- and sex-specific incidences for 
MSH6, PMS2 and MUTYH mutation carriers (26, 33, 34).     
The polygenic component for age t, Pi(t), was assumed to be normally distributed 
with zero mean and variance σ2p(t). P was approximated by the hypergeometric polygenic 
model (35, 36). We also fitted models where the variance of the polygenic ‘modifying’ 
component was allowed to take a different value σ2m for MMR gene and MUTYH carriers. 
To compute the baseline colorectal cancer incidence λ0(t), we constrained the overall 
incidence of colorectal cancer to agree with the national age- and sex-specific incidences 
(1998-2002) separately for Australia, Canada and USA (37). Other cancers were ignored in 
this model.  
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We assumed that the sensitivity of the mutation testing of probands for MMR genes 
and MUTYH was 80%,(38) and we examined the effect of varying this sensitivity.  For 
relatives, we assumed the mutation screening for the proband’s mutation (i.e. predictive 
testing) was 100% sensitive and specific.  
The genetic models were specified in terms of colorectal cancer incidence for MMR 
gene and MUTYH mutation carriers, the frequency (qA) of the putative high risk allele ‘‘A’’ 
of the unidentified major genes component, the average relative risk of colorectal cancer for 
carriers of mutations in the unidentified major genes, and the variances of the polygenic and 
modifying components (σ2p and σ2m). Maximum likelihood estimation was used to estimate 
parameters. The estimates we present are the values that were the most likely (i.e. most 
consistent) with the data. Maximum likelihood is the optimal method for making such 
estimates, and provides confidence intervals (CIs). We adjusted for ascertainment by 
maximizing the likelihood of each pedigree conditioned on the colorectal cancer status of the 
proband and his or her age of diagnosis (but not the mutation carrier status as this information 
was not known at the time of recruitment).  
The relative goodness of fit for nested models was tested by the likelihood ratio test. 
The Akaike’s Information Criterion(39) [AIC=-2xlog-likelihood + 2x(no. of parameters)] 
was used to assess goodness of fit between non- nested models (40).  
The expected versus observed number of affected relatives under each fitted model 
was assessed using the Pearson χ2 goodness of fit statistic. The expected number of probands 
with MMR and MUTYH mutation carriers for families that had undergone mutation testing 
based on their cancer family history was computed using Bayes theorem (41). Statistical 
methods are described further in the Appendix. 
  
 13
RESULTS 
A total of 5,744 families was eligible for inclusion, including 37,634 first-degree 
relatives of probands of whom 50% were female and 806 (2%) had been diagnosed with 
colorectal cancer (Table 1). Nearly two-thirds of the families were recruited from the USA 
(63%), with 16% and 21% of families recruited from Australia and Canada, respectively. 
Seventy-three percent of the probands were Caucasian whereas the rest were African 
American (17%), Asian (6%), Latino (1%), Native American (1%) and unknown (2%). 
Approximately 7% of all probands (N=386) had been found to have a MMR-deficient 
colorectal tumour and therefore had been screened for germline mutations in the MMR genes, 
while two-thirds of all probands (N=3,796) had been tested for germline mutations in 
MUTYH. Of the probands who were screened, 136 had a MMR gene mutation (49 in MLH1, 
39 in MSH2, 24 in MSH6 and 24 in PMS2) and 81 had a MUTYH mutation (63 monoallelic 
and 18 biallelic) (Table 2). 
All seven models that incorporated a polygenic component and the hypothetical 
unidentified major genes provided significantly better fits than the model that included only 
MMR gene and MUTYH mutation carriers (all P<0.001) (Supplementary Table 1). The mixed 
dominant model was essentially identical to a mixed codominant model in terms of fit 
(likelihood ratio test, P=0.94), but was more parsimonious given it used less parameters. All 
other models were rejected when compared with the mixed codominant model (likelihood 
ratio test, all P<0.001).  
When we allowed the polygenic variance to vary by age, the mixed dominant model 
for the unidentified major genes was the most parsimonious (i.e., had the lowest AIC) 
compared with all other models fitted (Table 3). Under this model, we estimated 0.19% (95% 
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CI, 0.04% – 1.08%) of the population carry mutations in unidentified major genes, and these 
are associated with on average a 31-fold (95% CI, 12 – 83) increased risk of colorectal 
cancer. The estimated variance of the polygenic component was 3.28 for age <40 years, 0.92 
for age 40-49 years, 0.46 for age 50-59 years, 0.79 for age 60-69 years, and 0.52 for age ≥70 
years. The proportion of polygenic variance after adjusting for the identified major genes 
explained by the unidentified major genes was 13%, 54%, 58%, 33% and 36% for ages <40, 
40-49, 50-59, 60-69 and ≥70 years, respectively (Figure 1). The estimated population carrier 
frequency for mutations in MLH1, MSH2, MSH6, PMS2, and monoallelic and biallelic 
MUTYH are shown in Table 4.  
Table 5 (A) shows the expected versus observed number of relatives of the probands, 
who developed colorectal cancer before age 80 years. Consistent with the AIC, the expected 
numbers from the mixed dominant model is closest to the observed numbers. 
Table 5 (B) shows the expected and observed number of probands who are mutation 
carriers for each MMR gene and monoallelic and biallelic MUTYH mutations. The expected 
numbers from the mixed dominant model with an age-dependent polygenic variance were 
closest to the observed numbers and had the lowest χ2 compared with other models. In 
general, all the models closely predicted the number of mutation carriers. 
In all the fitted models above, the sensitivity of mutation testing was fixed at 0.80. 
When we re-fitted the models assuming the sensitivity was 0.90, the impact was negligible. 
Model estimates were virtually identical when the unidentified major genes were fitted as a 
separate locus to the MMR mutations and MUTYH (not shown). 
Results were not materially different when we restricted analyses to Caucasian 
families (not shown). The relative risks for the unidentified major genes did not vary 
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appreciably by age in the major gene models (not shown).  There was virtually no evidence 
of a difference between the size of the polygenic variance for non-carriers σ2p and the 
modifying variance σ2m for any of the models (not shown).  
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DISCUSSION 
We have used a large population-based family data set from the Colon Cancer Family 
Registry, and existing penetrance estimates, to produce new estimates of the population 
prevalence of high-risk mutations in the identified major susceptibility genes for colorectal 
cancer: the DNA mismatch repair genes and MUTYH. We estimated that 1 in 279 (95% CI, 
192 – 403) of the population carry mutations in mismatch repair genes (MLH1 = 1 in 1946, 
MSH2 = 1 in 2841, MSH6 = 1 in 758, PMS2 = 1 in 714), and 1 in 45 carry mutations in 
MUTYH.  
Previously, researchers have inferred these carrier frequencies from the carrier 
frequency for cases, risk for the general population and risk for mutation carriers 
(Supplementary Table 2)(10-16). None, except those estimated by Song et al(16), were gene 
specific. Previous estimates of population carrier frequencies for the four MMR mutations 
combined (or MLH1 and MSH2 mutations combined) were similar to our estimates, except 
for those obtained by Dunlop et al(11). This discrepancy might be explained by different 
screening methods, and that knowledge about which mutations are truly pathogenic has 
improved substantially over time (30). For MUTYH mutations, a systematic review and meta-
analysis estimated the population carrier frequency of monoallelic MUTYH mutations to be 1 
in 60 and biallelic MUTYH mutations to be approximately 1 in 7,000, similar to our 
estimates(42). 
We then sought to explain the residual familial aggregation of this disease. We 
considered a polygenic component that proposes there are multiple independent loci, and 
across loci and at each locus, the alleles have a multiplicative effect on risk. We also 
considered the existence of one or more unidentified major genes (genes for which there are 
mutations associated with a high risk of colorectal cancer), and allowed for different modes 
of disease inheritance (dominant, recessive and codominant).  
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We found evidence that there exist as yet unidentified major colorectal cancer 
susceptibility genes, and their mode of inheritance was most likely dominant (thought this 
does not necessarily mean that they were all dominant). It is important to note that the 
apparent dominant component might also reflect missed mutations in MMR genes, MUTYH 
or APC because the mutation screening techniques used were not 100% sensitive and not all 
probands had been screened. We estimated that the 1 in 504 (95% CI, 93 – 2778) of the 
population carry unidentified mutations associated with an average 31-fold increased risk of 
colorectal cancer. The estimated polygenic variance was reduced by 30-50% after allowing 
for these unidentified major genes, after which it decreased from 3.3 for age <40 years to 0.5 
for age ≥70 years (equivalent to sibling relative risks of 5.1 to 1.3, respectively). 
The term ‘missing heritability’ has been variously defined over the last decade to refer 
to the fact that not all the causes of familial aggregation, or of familial aggregation considered 
to be due to genetic factors, have been found (43). The latter has been addressed by assuming 
an all-or-nothing unmeasured liability model that makes untestable assumptions (44). For the 
purposes of discussion here, we assume that heritability encapsulates both genetic and non-
genetic causes of familial aggregation. In this regard, it is plausible for common cancers that 
non-trivial heritability is due to non-genetic factors (45). In this paper, we have fitted a 
polygenic component to capture familial aggregation not explained by the major genes. It is 
based on an underlying genetic model of Fisher (1918)(46), but given are studying nuclear 
families it also represents non-genetic familial factors. That is, although it is labelled 
polygenic, it could also reflect the effect of environmental and lifestyle factors shared by 
first-degree relatives. Given that the polygenic variance is proportional to the log of the 
familial relative risk attributable to the polygenic component, the unidentified major genes 
might explain one-third to one-half of the missing heritability of colorectal cancer across the 
ages of 40 to 70 years. 
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The polygenic component will also capture the currently identified, and as yet 
unidentified, common SNPs associated with colorectal cancer risk. For example, the current 
45 independent susceptibility SNPs explain 22% of familial aggregation (20). It is likely this 
proportion will increase as larger studies are conducted, such as the OncoArray initiative, and 
as more informative statistical strategies are used to devise risk-prediction SNP-based scores 
other than the current highly conservative paradigm of considering each SNP individually 
and applying stringent penalties for multiple testing. The common SNPs identified to date are 
not necessarily causal, and they could also be tagging rare causal variants (as was the case for 
HOXB13 and prostate cancer (47)). 
Our analyses suggest a role for rare variants in as yet undiscovered susceptibility 
genes associated with high risk. Individually they could be very rare, and difficult to 
discover. One recent attempt to resolve this issue was a whole exome sequencing study that 
identified some high-risk mutations in candidate susceptibility genes such as POT1, POLE2 
and MRE11 (19). The authors concluded that the study “probably discounts the existence of 
further major high-penetrance susceptibility genes, which individually account for >1% of the 
familial risk”. Therefore, if both their and our findings are correct, there is likely to be 
perhaps hundreds of major genes each contributing little to the missing heritability. As well 
as sample size, the authors recognized that restriction to exomes limited their ability to 
identify pathogenic mutations outside of transcribed regions, and that targeted capture is 
insufficiently sensitive to detected copy number variation. We, therefore, agree with the 
authors in their conclusion that there is a need for very large-scale sequencing studies that 
would benefit from including highly informative families. 
Strengths of our study include a large number of families ascertained regardless of a 
family history, standardized questionnaires and protocols used by the Colon Cancer Family 
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Registry, and sophisticated statistical techniques that properly adjust for ascertainment and 
account for residual familial aggregation of disease (thereby avoiding bias). We also used a 
systematic approach for screening and testing of germline mutations in both MMR genes and 
MUTYH. 
When predicting the number of relatives with colorectal cancer, we did not 
differentiate family history of colorectal cancer in terms of tumor location within the bowel. 
This approach was supported by findings from a large study in Utah, which reported similarly 
elevated risks of colorectal cancer associated with a family history of colorectal cancer 
regardless of tumor location (proximal colon, distal colon, and rectum) (48). 
The response of the population-based probands approached to participate was 72% 
(49). MMR gene and MUTYH mutation carriers have both been associated with better 
colorectal cancer survival than non-carriers (50-52). Therefore, if probands with better 
prognosis are more likely to participate in the study, survivor bias could potentially lead to an 
overestimation of the mutation frequency. Data on participation differences by prognostic 
characteristics were not available to assess this. 
A potential limitation of our study is inaccurate reporting of family colorectal cancer 
history. Of the 806 colorectal cancer diagnoses reported by first-degree relatives, 26% were 
confirmed by pathology reports, clinic records or cancer registries. Previous studies have 
found reported colorectal cancer history in first-degree relatives to be reasonably accurate 
(85-90% agreement)(53) so even though the colorectal cancer diagnoses in relatives were not 
confirmed, it is unlikely to have a great impact on our results. 
Another potential limitation of our study is the reliance on external estimates of 
colorectal cancer relative risks for carriers of MMR gene and MUTYH mutations. To help 
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mitigate this weakness, we used estimates based on the largest studies available, and all used 
data from the same source, the Colon Cancer Family Registry (26, 32-34). Future studies 
should focus on incorporating the explicit effects of other colorectal cancer susceptibility 
genes such as STK11(54) BMPR1A(55), SMAD4, PTEN(56), POLE and POLD1(57) as well 
as the explicit effects of identified common low risk alleles(20). In addition to colorectal 
cancer risk, it is known that MMR gene mutations increase the risks of other cancers such as 
endometrial and ovarian cancer (58). Our analyses can be extended to incorporate such 
information. 
The polygenic variance describes the range of familial risk across a population at a 
given age. For example, given the estimated variances by age for the mixed dominant model, 
the familial relative risk was 5.1, 1.6, 1.3, 1.5 and 1.3 for ages <40, 40-49, 50-59, 60-69 and 
≥70 years, respectively. Although we found no evidence that the polygenic effects differed 
for carriers of a MMR gene mutation compared with non-carriers, this does not imply that 
they are due to the same variants. Some studies have shown that the common genetic variants 
identified through GWAS to be associated with the risk for the general population are not 
relevant for MMR gene mutation carriers (59). If future studies identify specific genetic 
modifiers of colorectal cancer risk for MMR gene or MUTYH mutation carriers, it should be 
possible to extend the current analyses to allow for this level of complexity. 
In conclusion, we have used a large population-based family study to estimate the 
prevalence of mutations in the identified major colorectal cancer-susceptibility genes, as well 
as the prevalence and relative risk of yet-to-be-discovered, high-risk susceptibility genes. 
This is an essential step in the development of a high quality-risk prediction model for 
colorectal cancer and is a major clinical and public health goal. Subsequently, screening 
programs can be optimized at an individual level to attain maximum benefit, however that 
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may be defined.  This study also provides a guidepost for future new gene discovery research 
and will justify, and guide, the use of next-generation sequencing to find these genes. The 
results show that our current understanding of hereditary predisposition to colorectal cancer is 
incomplete and supports the existence of yet undiscovered rare but highly penetrant 
mutations, while also underscoring that the polygenic component is still largely unresolved.  
  
 22
References 
1. Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA. Population-Based 
Family History-Specific Risks for Colorectal Cancer: A Constellation Approach. 
Gastroenterology. 2010;138:877-85. 
2. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007;21:2525-38. 
3. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch 
syndrome: 1895-2015. Nat Rev Cancer. 2015;15:181-94. 
4. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et al. 
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome 
due to deletion of the 3' exons of TACSTD1. Nat Genet. 2009;41:112-7. 
5. Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon 
of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum 
Mutat. 2009;30:197-203. 
6. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, et al. 
Identification of FAP locus genes from chromosome 5q21. Science. 1991;253:661-5. 
7. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of 
chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 1991;253:665-9. 
8. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. 
Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 
1991;66:589-600. 
9. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, et al. 
Inherited variants of MYH associated with somatic G:C -->T:A mutations in colorectal 
tumors. Nat Genet. 2002;30:227. 
 23
10. Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, et al. 
Population-Based Molecular Detection of Hereditary Nonpolyposis Colorectal Cancer. J Clin 
Oncol. 2000;18:2193-200. 
11. Dunlop MG, Farrington SM, Nicholl I, Aaltonen L, Petersen G, Porteous M, et al. 
Population carrier frequency of hMSH2 and hMLH1 mutations. Br J Cancer. 2000;83:1643-
5. 
12. Terdiman JP. HNPCC: an uncommon but important diagnosis. Gastroenterology. 
2001;121:1005-8. 
13. de la Chapelle A. The incidence of Lynch syndrome. Fam Cancer. 2005;4:233-7. 
14. Boland CR, Shike M. Report from the Jerusalem workshop on Lynch syndrome-
hereditary nonpolyposis colorectal cancer. Gastroenterology. 2010;139:2197 e1-7. 
15. Hampel H, de la Chapelle A. The Search for Unaffected Individuals with Lynch 
Syndrome: Do the Ends Justify the Means? Cancer Prev Res. 2011;4:1-5. 
16. Song W, Gardner SA, Hovhannisyan H, Natalizio A, Weymouth KS, Chen W, et al. 
Exploring the landscape of pathogenic genetic variation in the ExAC population database: 
insights of relevance to variant classification. Genet Med. 2016;18:850-4. 
17. Aaltonen L, Johns L, JÃ¤rvinen H, Mecklin J-P, Houlston R. Explaining the Familial 
Colorectal Cancer Risk Associated with Mismatch Repair (MMR)-Deficient and MMR-
Stable Tumors. Clin Cancer Res. 2007;13:356-61. 
18. Jenkins MA, Baglietto L, Dite GS, Jolley DJ, Southey MC, Whitty J, et al. After 
hMSH2 and hMLH1--what next? Analysis of three-generational, population-based, early-
onset colorectal cancer families. Int J Cancer. 2002;102:166-71. 
19. Chubb D, Broderick P, Dobbins SE, Frampton M, Kinnersley B, Penegar S, et al. 
Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. 
Nature communications. 2016;7:11883. 
 24
20. Jenkins MA, Makalic E, Dowty JG, Schmidt DF, Dite GS, MacInnis RJ, et al. 
Quantifying the utility of single nucleotide polymorphisms to guide colorectal cancer 
screening. Future Oncol. 2016;12:503-13. 
21. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon 
Cancer Family Registry: an international resource for studies of the genetic epidemiology of 
colon cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2331-43. 
22. Colon Cancer Family Registry. Available from: http://coloncfr.org 
23. Colon Cancer Family Registry Questionnaires. Available from: 
http://coloncfr.org/questionnaires 
24. Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA, et al. Use of 
molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset 
colorectal cancer. J Clin Oncol. 2005;23:6524-32. 
25. Rumilla K, Schowalter KV, Lindor NM, Thomas BC, Mensink KA, Gallinger S, et al. 
Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. 
J Mol Diagn. 2011;13:93-9. 
26. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The 
Clinical Phenotype of Lynch Syndrome Due to Germ-Line PMS2 Mutations. 
Gastroenterology. 2008;135:419-28. 
27. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. 
Sequence variant classification and reporting: recommendations for improving the 
interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282-91. 
28. Arnold S, Buchanan DD, Barker M, Jaskowski L, Walsh MD, Birney G, et al. 
Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, 
segregation, and tumor characteristics. Hum Mutat. 2009;30:757-70. 
 25
29. InSiGHT variant databases. Available from: http://insight-
group.org/variants/databases/ 
30. Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, et al. 
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch 
repair gene variants in the InSiGHT locus-specific database. Nat Genet. 2013;46:107-15. 
31. Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, et al. Germline 
MutY Human Homologue Mutations and Colorectal Cancer: A Multisite Case-Control Study. 
Gastroenterology. 2009;136:1251-60. 
32. Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, et al. 
Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2013;34:490-7. 
33. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, et al. 
Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers. J Natl Cancer Inst. 
2010;102:193-201. 
34. Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, et al. Risk of 
colorectal cancer for carriers of mutations in MUTYH, with and without a family history of 
cancer. Gastroenterology. 2014;146:1208-11.e1-5. 
35. Lange K. An approximate model of polygenic inheritance. Genetics. 1997;147:1423-
30. 
36. Fernando RL, Stricker C, Elston RC. The finite polygenic mixed model: An 
alternative formulation for the mixed model of inheritance. Genetics. 1994;88:573-80. 
37. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al., editors. 
Cancer Incidence in Five Continents, Vol. IX. Lyon, France: International Agency for 
Research on Cancer; 2007. 
 26
38. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP 
supplementary evidence review: DNA testing strategies aimed at reducing morbidity and 
mortality from Lynch syndrome. Genet Med. 2009;11:42-65. 
39. Akaike H. A new look at the statistical model identification. IEEE Trans Automat 
Control. 1974;19:716-23. 
40. Elston R. Models for discrimination between alternative modes of inheritance. In: 
Gianola D, Hammond F, editors. Advances in statistical methods for genetic improvement of 
livestock. Berlin: Springer; 1990. p. 41-55. 
41. Antoniou AC, Pharoah PPD, Smith P, Easton DF. The BOADICEA model of genetic 
susceptibility to breast and ovarian cancer. Br J Cancer. 2004;91:1580-90. 
42. Win AK, Hopper JL, Jenkins MA. Association between monoallelic MUTYH 
mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer. 2011;10:1-9. 
43. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. 
Finding the missing heritability of complex diseases. Nature. 2009;461:747-53. 
44. Hopper JL, Mack TM. The heritability of prostate cancer-letter. Cancer Epidemiol 
Biomarkers Prev. 2015;24:878. 
45. Hopper JL, Carlin JB. Familial Aggregation of a Disease Consequent upon 
Correlation between Relatives in a Risk Factor Measured on a Continuous Scale. Am J 
Epidemiol. 1992;136:1138-47. 
46. Fisher RA. The correlation between relatives on the supposition of Mendelian 
inheritance. Transactions of the royal society of Edinburgh. 1918;52:399-433. 
47. MacInnis RJ, Severi G, Baglietto L, Dowty JG, Jenkins MA, Southey MC, et al. 
Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense 
mutation G84E. PLoS One. 2013;8:e54727. 
 27
48. Samadder NJ, Smith KR, Mineau GP, Pimentel R, Wong J, Boucher K, et al. Familial 
colorectal cancer risk by subsite of primary cancer: a population-based study in Utah. 
Aliment Pharmacol Ther. 2015. 
49. Jang JH, Cotterchio M, Gallinger S, Knight JA, Daftary D. Family history of 
hormonal cancers and colorectal cancer risk: a case-control study conducted in Ontario. Int J 
Cancer. 2009;125:918-25. 
50. Nielsen M, van Steenbergen LN, Jones N, Vogt S, Vasen HFA, Morreau H, et al. 
Survival of MUTYH-Associated Polyposis Patients With Colorectal Cancer and Matched 
Control Colorectal Cancer Patients. J Natl Cancer Inst. 2010;102:1724-30. 
51. Watson P, Lin KM, Rodriguez-Bigas MA, Smyrk T, Lemon S, Shashidharan M, et al. 
Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family 
members. Cancer. 1998;83:259-66. 
52. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients 
with MLH1-associated hereditary colorectal cancer. Gastroenterology. 1996;110:682-7. 
53. Mai PL, Garceau AO, Graubard BI, Dunn M, McNeel TS, Gonsalves L, et al. 
Confirmation of family cancer history reported in a population-based survey. J Natl Cancer 
Inst. 2011;103:788-97. 
54. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker SV, 
et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987;316:1511-
4. 
55. Haidle JL, Howe JR. Juvenile Polyposis Syndrome. In: Pagon RA, Bird TD, Dolan 
CR, Stephens K, editors. Gene Reviews. Seattle, WA: University of Washington, Seattle; 
1993-. 
56. Mallory SB. Cowden syndrome (multiple hamartoma syndrome). Dermatol Clin. 
1995;13:27-31. 
 28
57. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. 
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to 
colorectal adenomas and carcinomas. Nat Genet. 2013;45:136-44. 
58. Win AK, Young JP, Lindor NM, Tucker K, Ahnen D, Young GP, et al. Colorectal 
and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair 
gene mutation: a prospective cohort study. J Clin Oncol. 2012;30:958-64. 
59. Win AK, Hopper JL, Buchanan DD, Young JP, Tenesa A, Dowty JG, et al. Are the 
common genetic variants associated with colorectal cancer risk for DNA mismatch repair 
gene mutation carriers? Eur J Cancer. 2013;49:1578-87. 
 
 
 
 29
Table 1: Descriptive statistics of population-based families from the Colon Cancer Family Registry 
 All Australia USA Canada 
Relative of 
proband 
Total 
No. 
No. of CRC 
affected (%) 
Mean age at 
CRC diagnosis 
(SD) 
Total 
No. 
No. of 
CRC 
affected 
(%) 
Mean age 
at CRC 
diagnosis 
(SD) 
Total 
No. 
No. of CRC 
affected 
(%) 
Mean age at 
CRC 
diagnosis 
(SD) 
Total 
No. 
No. of 
CRC 
affected 
(%) 
Mean age 
at CRC 
diagnosis 
(SD) 
Proband 5744 5744 (100) 52.5 (11.6) 911 911 (100) 45.8 (8.0) 3626 3626 (100) 54.7 (11.8) 1207 1207 (100) 50.7 (10.9) 
Father 5737 305 (5) 61.6 (11.0) 911 68 (7) 61.3 (12.2) 3626 164 (5) 61.9 (10.8) 1200* 73 (6) 61.3 (10.5) 
Mother 5737 234 (4) 61.5 (12.1) 911 48 (5) 61.7 (11.1) 3626 142 (4) 62.2 (12.4) 1200* 44 (4) 59.2 (12.0) 
Sibling 15095 255 (2) 56.0 (13.3) 2228 26 (1) 47.2 (14.1) 9437 183 (2) 57.3 (12.4) 3430 46 (1) 55.6 (14.4) 
Offspring 11065 12 (0.1) 40.3 (14.4) 1772 2 (0.1) 23.0 (8.5) 6884 8 (0.1) 46.9 (11.0) 2409 2 (0.1) 31.5 (16.3) 
CRC, colorectal cancer; SD, standard deviation 
*7 probands had no data for father and mother 
 
Table 2: Descriptive statistics of population-based families from the Colon Cancer Family Registry by mismatch repair (MMR) gene and 
MUTYH mutation carrier status 
 MMR gene mutation families (n=136) MUTYH gene mutation families (n=81) Non-carrier / unidentified carrier status families 
(n=5528) 
Relative 
of 
proband 
Total No. No. of CRC 
affected (%) 
Mean age at CRC 
diagnosis (SD) 
Total No. No. of CRC 
affected (%) 
Mean age at CRC 
diagnosis (SD) 
Total No. No. of CRC 
affected (%) 
Mean age at CRC 
diagnosis (SD) 
Proband 136 136 (100) 42.9 (10.5) 81 81 (100) 50.1 (12.3) 5528 5528 (100) 52.7 (11.5) 
Father  136 26 (19) 49.0 (14.4) 81 8 (10) 67.8 (7.0) 5501* 271 (5) 62.7 (10.0) 
Mother 136 16 (12) 51.4 (12.6) 81 0 (0) - 5501* 218 (4) 62.3 (11.7) 
Sibling 375 27 (8) 41.7 (11.5) 181 4 (2) 63.3 (9.9) 14494 224 (2) 57.6 (12.5) 
Offspring 207 0 (0) - 150 0 (0) - 10665 12 (0.1) 40.3 (14.4) 
CRC, colorectal cancer; SD, standard deviation 
One proband had both a MMR gene and a monoallelic MUTYH germline mutation. 
*7 probands had no data for father and mother 
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Table 3: Segregation analysis models including age-dependent polygenic variance, mismatch repair gene and MUTYH mutation carrier status 
Model No. 
Par 
LL AIC P* qA (95% 
CI) 
RR 
Het 
(95% 
CI) 
RR 
Hom 
(95% 
CI) 
σ2p  
(<40y) 
(95% CI) 
σ2p 
(40-49y) 
(95% CI) 
σ2p 
(50-59y) 
(95% 
CI) 
σ2p 
(60-69y) 
(95% CI) 
σ2p 
(>=70y) 
(95% 
CI) 
q(MLH1) 
(95% CI) 
q(MSH2) 
(95% CI) 
q(MSH6) 
(95% CI) 
q(PMS2) 
(95% CI) 
q(MUTYH) 
(95% CI) 
Polygenic 10 -7218.1 14456.1 0.01 – – – 3.74 
(1.47, 
9.51) 
2.02 
(1.17, 
3.48) 
1.11 
(0.64, 
1.91) 
1.19 
(0.74, 
1.90) 
0.80 
(0.42, 
1.54) 
0.000261 
(0.000198, 
0.000342) 
0.000181 
(0.000134, 
0.000244) 
0.000664 
(0.000447, 
0.000987) 
0.000701 
(0.000474, 
0.001047) 
0.01113 
(0.00950, 
0.01304) 
Mixed 
Dominant 
12 -7212.5 14449.0 1.0 0.000992 
(0.00018, 
0.00541) 
31.1 
(11.6, 
83.4) 
31.1 
(11.6, 
83.4) 
3.28 
(1.10, 
9.74) 
0.93 
(0.26, 
3.32) 
0.46 
(0.12, 
1.81) 
0.78 
(0.27, 
2.27) 
0.52 
(0.16, 
1.64) 
0.000257 
(0.000195, 
0.000338) 
0.000176 
(0.000130, 
0.000238) 
0.000660 
(0.000444, 
0.000982) 
0.000701 
(0.000471, 
0.001042) 
0.01113 
(0.00950, 
0.01304) 
Mixed 
Recessive 
12 -7216.1 14456.2 0.007 0.151 
(0.057, 
0.403) 
1.0 10.8 
(3.5, 
33.4) 
3.28 
(1.24, 
8.64) 
1.50 
(0.70, 
3.21) 
0.69 
(0.27, 
1.79) 
0.82 
(0.35, 
1.94) 
0.64 
(0.25, 
1.64) 
0.000261 
(0.000198, 
0.000343) 
0.000180 
(0.000133, 
0.000244) 
0.000663 
(0.000446, 
0.000985) 
0.000703 
(0.000473, 
0.001045) 
0.01109 
(0.00947, 
0.01299) 
Mixed 
Codominant 
13 -7212.5 14451.0 – 0.000992 
(0.00018, 
0.00541) 
31.1 
(11.6, 
83.4) 
31.1 
(11.6, 
83.4) 
3.28 
(1.10, 
9.74) 
0.93 
(0.26, 
3.32) 
0.46 
(0.12, 
1.81) 
0.78 
(0.27, 
2.27) 
0.52 
(0.16, 
1.64) 
0.000257 
(0.000195, 
0.000338) 
0.000176 
(0.000130, 
0.000238) 
0.000660 
(0.000444, 
0.000982) 
0.000701 
(0.000471, 
0.001042) 
0.01113 
(0.00950, 
0.01304) 
Par, number of parameters estimated in the model; LL, log-likelihood; AIC, Akaile’s Information Criterion; qA, estimated high-risk allele 
frequency for the unidentified major genes; q, minor allele frequency; CI, confidence interval; hom, homozygous; het, heterozygous, RR, 
relative risk as compared with non-carriers; σ2p, variance of the polygenic component; –, not applicable. 
*For all models, P value refers to the comparison with the mixed codominant model using the log-likelihood ratio test.  
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Table 4: Estimated population carrier frequency for each mismatch repair (MMR) gene, 
MUTYH and the unidentified major susceptibility genes based on the mixed dominant model 
with age-dependent polygenic component 
Gene % (95% CI) 1 in (95% CI) 
Unidentified major genes 0.198 (0.036 – 1.079) 504 (93 – 2778) 
MLH1 0.051 (0.039 – 0.068) 1946 (1480 – 2564) 
MSH2 0.035 (0.026 – 0.048) 2841 (2101 – 3846) 
MLH1 or MSH2 0.087 (0.065 – 0.115) 1155 (868 – 1539) 
MSH6 0.132 (0.089 – 0.196) 758 (509 – 1126) 
PMS2 0.140 (0.094 – 0.208) 714 (480 – 1062) 
Any MMR gene 0.359 (0.248 – 0.520) 279 (192 – 403) 
MUTYH monoallelic 2.214 (1.891 – 2.591) 45 (39 – 53) 
MUTYH biallelic 0.012 (0.009 – 0.017) 8073 (5881 – 11080) 
 
CI, confidence interval; MMR, mismatch repair 
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Table 5 (A): Expected versus observed number of colorectal cancer affected relatives  
 1 
parent 
1 
sibling 
2 
siblings
1 parent 
1 sibling 
χ2 
Observed 478 175 14 28  
Expected       
- Polygenic  466.9 189.8 9.6 21.7 5.3 
- Mixed dominant 462.4 179.6 9.4 24.2 3.5 
- Mixed recessive 451.9 200.1 10.8 22.4 7.0 
- Mixed codominant 462.4 179.6 9.4 24.2 3.5 
χ2 value for the difference between observed and expected number of affected relatives. 
Note, the lower the χ2, the better the fit of the model.5 
 
Table 5 (B): Expected versus observed number of mutation carriers in families that had 
mutation testing performed 
 MLH1 MSH2 MSH6 PMS2 MUTYH
biallelic 
MUTYH 
monoallelic 
χ2 
Number of families 3319 3319 3319 3319 3796 3796  
Observed 49 39 24 24 18 63  
Expected  
- Polygenic 49.3 43.8 24.9 24.9 18.3 66.6 0.8 
- Mixed dominant 48.7 42.5 24.7 24.6 18.2 66.6 0.5 
- Mixed recessive 49.4 43.9 24.7 24.7 17.9 66.3 0.8 
- Mixed codominant 48.7 42.5 24.7 24.6 18.2 66.6 0.5 
χ2 value for the difference between observed and expected number of mutation carriers. 
Note, the lower the χ2, the better the fit of the model. 
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Figure 1. Amount of polygenic variance explained by the hypothetical unidentified major 
genes component (dark grey) and the polygenic component (white) for each 10-year age 
group. 
 
 1
Statistical Methods 
We used modified segregation analysis to fit a range of genetic models to the observed 
colorectal cancer family histories for the proband and their first-degree relatives. Information 
on second-degree relatives and other relatives of the proband were not used for this analysis 
as data were incomplete. Individuals were assumed to be at risk of colorectal cancer from 
birth until the earliest of the following: diagnosis of colorectal cancer or any other cancer 
(except skin cancer), first polypectomy, death, the earlier of last known age at baseline 
interview or age 80 years. Individuals known to have died but with unknown age at death 
were censored at age 70 years. Relatives reported to have had colorectal cancer with 
unknown age at diagnosis were assigned an age at diagnosis as their age of death (if 
deceased) or their age at the time of the proband’s baseline interview. Relatives with no age 
information were treated as lost to follow-up with age censored at zero years.  
Models of Susceptibility 
The model we used was an extension of the mixed model of Morton and MacLean (1974) (1). 
incorporating both major gene and polygenic components. In our model, the colorectal cancer 
incidence λi(t,k) for individual i at age t in sex group k (k = 1 for males, k = 2 for females) 
was assumed to depend on genotype according to a parametric survival analysis model λ
i(t,k)=λ0(t,k) exp(Gi+Pi(t)), where λ0(t,k) is the sex-specific baseline incidence at age t . Gi 
is the natural logarithm of the relative risk associated with the major genotype and Pi(t) is the 
polygenic component for age t.  
The major genotype was defined by six components representing each of the genes: MLH1, 
MSH2, MSH6, PMS2, MUTYH and one representing the hypothetical unidentified major 
genes, here given the name UNIDENTIFIED_MAJOR_GENES. As the probability of having 
 2
a mutation in more than one of MLH1, MSH2, MSH6, PMS2, MUTYH was very small, to 
reduce the computation time, we coded these genes into one locus with seven alleles: MLH1 
positive, MSH2 positive, MSH6 positive, PMS2 positive, MUTYH positive, 
UNIDENTIFIED_MAJOR_GENES positive and a normal allele. For simplicity, the 
hierarchical order in which mutations were assumed to be dominant over other alleles was as 
follows: MLH1, MSH2, MSH6, PMS2, MUTYH, UNIDENTIFIED_MAJOR_GENES and 
normal alleles. These assumptions are not critical to the model because carriers in multiple 
genes are rare. Thus, Gi takes on the following potential risk categories: MLH1 carriers, 
MSH2 carriers, MSH6 carriers, PMS2 carriers, MUTYH biallelic carriers, MUTYH 
monoallelic carriers, UNIDENTIFIED_MAJOR_GENES heterozygotes, 
UNIDENTIFIED_MAJOR_GENES homozygotes and non-carriers. We fitted models in 
which the unidentified major genes component was autosomal  with a normal and a mutant 
allele unlinked to mutations in the MMR genes or MUTYH. These assumptions are not 
critical to the model because carriers in multiple genes are rare. This is consistent with 
observation, since in this data set, there were no probands observed with mutations in more 
than one MMR gene. We have also previously observed that having MUTYH monoallelic 
mutation does not significantly alter the risk of colorectal cancer in addition to having a 
MMR mutation (2, 3). We also fitted models in which the average relative risk for the 
unidentified major genes component was assumed to be age dependent. As the number of 
MMR and MUTYH mutation carriers in our dataset was too small to obtain reliable colorectal 
cancer risk estimates for mutation carriers, we used the published age-, sex- and country-
specific incidence rates for MLH1 and MSH2 mutation carriers (4), and published age- and 
sex-specific incidence rates for MSH6, PMS2 and MUTYH mutation carriers (2, 5, 6).     
The polygenic component for age t, Pi(t), was assumed to be normally distributed with zero 
mean and variance σ2p(t) . Because the standard polygenic model is not amenable to 
 3
“peeling” (7-9), we used as an approximation the hypergeometric polygenic model (HPM) 
(10, 11). P was approximated by P=(R-N)σp/(N/2)1/2, where R has a binomial distribution 
Bin(2N, 1/2). N, the number of loci used in the HPM, was set to 3 (see Appendices in 
Antoniou et al. (2001) for further details of the model(12)). We also fitted models where the 
variance of the polygenic ‘modifying’ component was allowed to take a different value σ2m 
for MMR and for MUTYH carriers. 
To compute the baseline colorectal cancer incidence λ0(t), we constrained the overall 
incidence of colorectal cancer to agree with the national age and sex specific incidences 
(1998-2002) separately for Australia, Canada and USA (13). Other cancers were ignored in 
this model. Published incidences are reported in 5-year intervals, which can result in large 
variation in incidences between adjacent age intervals, so we smoothed the population 
incidences using locally weighted regression (LOWESS)(14) with a bandwidth of 0.2.  
We assumed that the sensitivity of the mutation testing of probands for MMR genes and 
MUTYH was 80% (15), and we examined the effect of varying this sensitivity.  For relatives, 
we assumed the mutation screening for the proband’s mutation (i.e. predictive testing) was 
100% sensitive and specific.  
Estimation 
The genetic models were specified in terms of colorectal cancer incidence for MMR gene and 
MUTYH mutation carriers, the frequency (qA) of the putative high risk allele ‘‘A’’ of the 
unidentified major genes, the average relative risk of colorectal cancer for carriers of 
mutations in the unidentified major genes, the number of polygenic loci assumed in the HPM 
(N), and the variances of the polygenic and modifying components (σ2p and σ2m). 
Maximum likelihood estimation was used to estimate the parameters. The estimates we 
 4
present are the values that were the most likely (i.e. most consistent) with the data. Maximum 
likelihood is the optimal method for making such estimates, and provides confidence 
intervals (CIs). We adjusted for ascertainment by maximizing the likelihood of each pedigree 
conditioned on the colorectal cancer status of the proband and his or her age of diagnosis (but 
not mutation carrier status as this information was not known at the time of recruitment). The 
variances of the parameter estimates were obtained by inverting the observed information 
matrix. To allow for the restricted ranges of the parameter values and to provide estimates 
likely to be more nearly normally distributed, we used transformed values of the parameters 
as a basis for calculating CIs: the high-risk allele frequencies qA were transformed using the 
logit function log[p/(1–p)], while for relative risk and σ2p we used the log transformation. 
Goodness of Fit 
The relative goodness of fit for nested models was tested by the likelihood ratio test. The 
Akaike’s Information Criterion(16) [AIC=-2 log-likelihood + 2x(no. of parameters)] was 
used to assess goodness of fit between non-nested models (1).  
Estimation of Familial Relative Risk 
The familial relative risk of the polygenic component was estimated using exp(σ2 /2) (17). 
Expected versus Observed Number of Affected Relatives  
The goodness of fit of the models was assessed by comparing the observed number of 
affected relatives with that expected under each model. For each model, we computed the 
predicted number of probands with one parent with colorectal cancer, one sibling with 
colorectal cancer, two siblings with colorectal cancer and one parent and one sibling with 
colorectal cancer. The probability of observing each of these events for a family was  
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computed from the ratio of likelihoods for two pedigrees: the likelihood for a family in which 
the predicted event occurred and the likelihood of the affected proband (12). The expected 
versus observed number of affected relatives under each fitted model was assessed using the 
Pearson χ2 goodness of fit statistic Σj[(Oj-Ej)2/Ej] where Oj is the observed number of 
probands or families with a particular characteristic and Ej is the corresponding predicted 
numbers under each model. 
Expected versus Observed number of Mutation Carriers 
The expected number of probands with MMR and MUTYH mutation carriers for families that 
had undergone mutation testing based on their cancer family history was computed using 
Bayes theorem (18). For example, P(MLH1 carrier | family history) = P(MLH1 carrier, 
family history) / ΣP(mutation carrier status, family history) = L1/(L0+L1+L2+L3+L4+L5), 
where Li is the likelihood of observing the family with the proband carrying mutation i (=0, 1, 
2, 3, 4, 5 for mutation negative, MLH1, MSH2, MSH6, PMS2 and MUTYH, respectively). 
These probabilities were then added over all families to compute the total number of 
probands expected to carry a mutation for each gene (12). 
Statistical Computation 
Segregation analyses were performed using an optimised version(19) of the pedigree analysis 
software MENDEL version 3.2 (20). Incidence smoothing and other descriptive statistics 
were calculated using STATA 13.0 (21). 
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Supplementary Table 1: Results of segregation analyses incorporating mismatch repair gene and MUTYH mutation carrier status 
 No. 
Par 
LL AIC P* qA (95% CI) RR Het (95% 
CI) 
RR Hom (95% 
CI) 
σ2p (95% 
CI) 
q(MLH1) (95% 
CI) 
q(MSH2) 
(95% CI) 
q(MSH6) 
(95% CI) 
q(PMS2) 
(95% CI) 
q(MUTYH) 
(95% CI) 
Base 5 -7296.0 14602.0 3.8x10-33 – – – – 0.000313 
(0.000240, 
0.000407) 
0.000234 
(0.000177, 
0.000309) 
0.000701 
(0.000472, 
0.001042) 
0.000753 
(0.000508, 
0.001118) 
0.01135 
(0.00969, 
0.01330) 
Dominant 7 -7229.0 14472.0 6.0x10-6 0.00202 
(0.00087,0.00468) 
28.8 
(17.6,47.1) 
28.8 
(17.6,47.1) 
– 0.000275 
(0.000209, 
0.000361) 
0.000191 
(0.000141, 
0.000258) 
0.000668 
(0.000450, 
0.000993) 
0.000712 
(0.000479, 
0.001059) 
0.01118 
(0.00954, 
0.01310) 
Recessive 7 -7238.1 14490.2 6.5x10-10 0.1804 
(0.11,0.296) 
1.0 19.0 
(11.0,32.7) 
– 0.000284 
(0.000216, 
0.000372) 
0.000203 
(0.000151, 
0.000272) 
0.000667 
(0.000449, 
0.000992) 
0.000711 
(0.000479, 
0.001057) 
0. 01113 
(0.00950, 
0.01304) 
Codomina
nt 
8 -7227.2 14470.3 6.2x10-6 0.007024 
(0.0032,0.0152) 
14.0 
(9.0,22.0) 
830.5 
(261.5,2637.1) 
– 0.000272 
(0.000206, 
0.000357) 
0.000189 
(0.000140, 
0.000256) 
0.000667 
(0.000449, 
0.000991) 
0.000711 
(0.000479, 
0.001057) 
0. 01114 
(0.00951, 
0.01305) 
Polygenic 6 -7223.6 14459.2 0.004 – – – 1.32 
(1.08,1.62) 
0.000272 
(0.000208, 
0.000357) 
0.000191 
(0.000142, 
0.000257) 
0.000667 
(0.000449, 
0.000992) 
0.000705 
(0.000474, 
0.001047) 
0. 01119 
(0.00955, 
0.01311) 
Mixed 
Dominant 
8 -7217.0 14449.9 0.94 0.00063 
(0.00010,0.00398) 
40.5 
(13.2,124.1) 
40.5 
(13.2,124.1) 
0.87 
(0.53,1.41) 
0.000263 
(0.000199, 
0.000346) 
0.000181 
(0.000133, 
0.000245) 
0.000662 
(0.000445, 
0.000984) 
0.000701 
(0.000471, 
0.001041) 
0. 01116 
(0.00953, 
0.01307) 
Mixed 
Recessive 
8 -7221.2 14458.3 0.004 0.116 
(0.046,0.290) 
1.0 
 
14.7 
(4.8,45.0) 
1.04 
(0.71,1.52) 
0.000270 
(0.000206, 
0.000354) 
0.000189 
(0.000140, 
0.000254) 
0.000664 
(0.000447, 
0.000987) 
0.000702 
(0.000473, 
0.001044) 
0. 01112 
(0.00949, 
0.01303) 
Mixed 
Codomina
nt 
9 -7216.9 14451.9 – 0.00062 
(0.00009,0.00412) 
40.8 
(12.8,129.6) 
19.6 
(0,∞) 
0.87 
(0.53,1.41) 
0.000262 
(0.000199, 
0.000345) 
0.000179 
(0.000132, 
0.000244) 
0.000662 
(0.000445, 
0.000984) 
0.000701 
(0.000472, 
0.001042) 
0. 01115 
(0.00952, 
0.01306) 
Par, number of parameters estimated in the model; LL, log-likelihood; AIC, Akaile’s Information Criterion; qA, estimated high-risk allele frequency for the unidentified major 
genes; q, minor allele frequency; CI, confidence interval; hom, homozygous; het, heterozygous, RR, relative risk as compared with non-carriers; σ2p, variance of the 
polygenic component; –, not applicable. 
*For all models, P value refers to the comparison with the mixed codominant model using the log-likelihood ratio test.  
 
Supplementary Table 2. Estimated population carrier frequency of a mismatch repair gene or MUTYH 
mutation from previous studies and current study 
Author Population Gene Estimate of 
population carrier 
frequency (95% CI) 
Calculation of carrier frequency based on 
these assumptions. 
Salovaara et al. (2000) (1) Finland MLH1, 
MSH2 
1 in 740 2.7% carrier frequency in CRC ×  
5% lifetime risk of CRC =  
0.135% 
Dunlop (2000) (2) Scotland (15-74 
years) 
MLH1, 
MSH2 
1 in 3139 (1247 - 7626) 2.66% carrier frequency in CRC ×  
0.17% population prevalence of CRC ÷ 14.6% 
prevalence of CRC in carriers = 0.031%  
Terdiman (2001) (3) USA MLH1, 
MSH2 
1 in 800 - 1 in 1600 1-2% carrier frequency in CRC ×  
5% lifestyle risk of CRC ÷  
80% lifetime risk for carriers =  
0.0625% to 0.125% 
de la Chapelle (2005) (4) Literature review MLH1, 
MSH2 
1 in 660 - 1 in 2000 1-3% carrier frequency in CRC ×  
5% lifetime risk of CRC =  
0.05% to 0.15% 
Boland and Shike (2010) 
(5) 
USA MLH1, 
MSH2, 
MSH6, 
PMS2 
1 in 300 2.8% carrier frequency in CRC ×  
6% lifetime risk of CRC ÷  
50% lifetime risk for carriers =  
0.33% 
Hampel and de la Chapelle 
(2011) (6) 
USA MLH1, 
MSH2, 
MSH6, 
PMS2 
1 in 370 2.8% carrier frequency in CRC ×  
5% lifetime risk of CRC ÷  
50% lifetime risk for carriers =  
0.28% 
Win et al. (2011) (7) Literature review MUTYH mono MUTYH 1 in 60 
bi MUTYH 1 in 7320 
243 monoallelic carriers ÷ 14639 controls 
2 biallelic carriers ÷ 14639 controls 
 
CRC, colorectal cancer; CI, confidence interval 
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